The U.S. Chamber submitted comments to the European Commission as it considers revisions and updates to its General Pharmaceuticals Legislation, which is Europe’s attempt to foster innovation, improve the resiliency of the healthcare sector in Europe, bolster supply chain security, and ensure access to innovative medicines across the EU. We encouraged the EU to do a better job of rewarding and prioritizing innovation, guarantee strong IP protections for manufacturers, and preserve open and integrated global supply chains rather than attempting to cut Europe off from the global economy in healthcare. We also focused on the importance of digital health and transatlantic coordination, including for research and pandemic response and recovery.
Recommended
- International
How the U.S. Can Help Ukraine Rebuild and Grow Its Economy
The 2024 U.S.-Ukraine Partnership Forum explored public and private sector opportunities to support economic development and recovery in Ukraine.
- International
EXIM Bank’s Environmental Critics Miss the Mark
By Martin Durbin - International
U.S.-Japan Summit Highlights Booming Business Opportunities
By Tomoko Hosaka Mullaney
- International
Africa’s Digital Transformation: Closing the Digital Divide
By Kendra Gaither
View this online